Exelixis, Inc. (LON: 0IJO)

Market Cap	7.62B
Revenue (ttm)	1.55B
Net Income (ttm)	348.37M
Shares Out	n/a
EPS (ttm)	1.15
PE Ratio	21.88
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,413
Average Volume	3,734
Open	36.65
Previous Close	36.75
Day's Range	32.93 - 36.65
52-Week Range	17.42 - 36.65
Beta	n/a
RSI	44.54
Earnings Date	Feb 6, 2025

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1994
• Employees: 1,310
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IJO

Financial Performance

In 2023, Exelixis's revenue was $1.83 billion, an increase of 13.60% compared to the previous year's $1.61 billion. Earnings were $207.77 million, an increase of 13.98%.

Financial numbers in USD